Treatment of Fabry’s Disease with the Pharmacologic Chaperone MigalastatDominique P. Germain, Raphael Schiffmann, William R. Wilcox et al.|New England Journal of Medicine|2016Cited by 555
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialRaphael Schiffmann, Derralynn Hughes, Özlem Göker-Alpan et al.|Journal of Inherited Metabolic Disease|2019Cited by 137
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE projectRafael Marcos‐Gragera, Claudia Allemani, Carmen Ţereanu et al.|Haematologica|2011Cited by 74